Helixor® M for Solid Tumors

"To date, 225 clinical trials for Helixor® M have been initiated in 2395 cities and 74 nations. The first of these studies was sponsored by Genzyme (a Sanofi Company) back in 2007 with 698 participants; it culminated into a Phase 3 drug approval stage. In the 14 years since then, 297 further such investigations have taken place."

"This clinical trial is seeking 58 participants with a malignancy aged between 18 and 100. To qualify, applicants must have not previously been exposed to mistletoe therapy, received first-line systemic treatment for metastatic disease that has either progressed or become refractory due to toxicities (other cases may be considered on an individual basis), demonstrate measurable lesions according to RECIST 1.1 criteria, have ECOG performance status of 0-2, life expectancy of greater than 3 months, WBC ≥3 000/mcL Absolute neutrophil count ≥1000/mcL Platelets ≥90 000/mcL Hemoglobin ≥9"

"Helixor® M is generally prescribed to those suffering from ovarian cancer, however it can also be utilized to address unresectable thymoma, locally advanced nonsquamous non-small cell lung cancer, and mesotheliomas."

"This medical trial is available to patients between the ages of 18-100, as per the defined eligibility requirements."

"It appears that clinicaltrials.gov does not currently list this trial as actively recruiting participants; the study was first published on March 1st 2017 and last edited on October 31st 2022. Although this particular study is inactive, there are 2810 other active studies looking for volunteers at present."

"This research program is no longer enrolling participants, with the last update to its listing occurring on October 31st 2022. If you are searching for other studies, there are 2585 active cancer-focused trials and 225 seeking patients for Helixor® M treatments available presently."

"Presently, 225 active trials are being conducted to evaluate the efficacy of Helixor® M. Of these studies, 87 have progressed to Phase 3 and are taking place across 19466 different medical sites; most of which can be found in Winston-Salem, North carolina."

"With limited clinical data in regards to safety and efficacy, Helixor® M only received a score of 1."